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Things Are Not Always
What They Seem
Shishehbor et al. (1) performed an analysis of outcomes after
3 strategies for treating cardiac surgery patients with concurrent
carotid disease. They concluded (in a cohort of predominantly
asymptomatic patients with unilateral carotid disease) that staged
carotid artery stenting (CAS) and open-heart surgery (OHS) and
combined carotid endarterectomy (CEA) and OHS have similar
procedural risks but that outcomes favored staged CAS-OHS
after the ﬁrst year. In a subsequent interview, Dr. Shishehbor
urged readers to “remember the whole point of doing this is to
prevent stroke” (2). Shishehbor et al. (1) are absolutely correct in their
statement, and it is therefore inexplicable that not once in the
group’s report did the investigators mention that there is a fourth
treatment strategy, namely, to perform no prophylactic carotid inter-
vention at all.
The Shishehbor et al. (1) study was based on 3 assumptions:
ﬁrst, that carotid disease is an important cause of stroke after
coronary artery bypass grafting (CABG); second, that patients with
asymptomatic carotid stenoses are at excess risk for stroke; and
third, that prophylactic CEA or CAS can reduce this risk. Un-
fortunately, at least 2 of these assumptions do not stand up to
scrutiny. First, 3 large natural-history studies (including 23,557
patients) showed that 95% of all post-CABG strokes cannot be
attributed to carotid disease (3–5). Second, an extensive systematic
review and meta-analysis showed that patients with unilateral,
asymptomatic carotid stenoses face a very small risk for ipsilateral
stroke (6). In addition, another systematic review showed that the
risk for stroke ipsilateral to the nonoperated severe carotid stenosis
in patients with bilateral severe carotid disease undergoing syn-
chronous CEA plus CABG was extremely low (7). If carotid
disease were responsible for a signiﬁcant proportion of post-CABG
strokes, the opposite should have been found.
The rationale underpinning prophylactic CEA or CAS is that it
reduces the risk for stroke after CABG. The prevention of late
stroke is not relevant to this debate. Accordingly, no one should
criticize anyone offering synchronous CEA and CABG or staged
CAS and CABG in patients reporting histories of transient
ischemic attack or stroke. It has long been accepted that these
patients really are at higher risk for post-CABG stroke. However,
the evidence justifying prophylactic CEA or CAS before CABG
JACC Vol. 63, No. 13, 2014 Correspondence
April 8, 2014:1335–44
1339in patients with unilateral, asymptomatic stenoses is tenuous, to say
the very least. Accordingly, the statement in an accompanying
editorial by Mahmud and Reeves (8) that this study “provides
clarity for the management of patients with carotid and coronary
disease” is not supported on the basis of currently available evi-
dence. Moreover, the caveat that surgeons are loath to perform
isolated CABG in this situation and that Shishehbor et al.’s (1)
study represents “real-world practice” cannot be used to justify an
uncritical policy of prophylactic carotid interventions with little or
no supporting evidence.*A. Ross Naylor, MD
*Vascular Research Group
Division of Cardiovascular Sciences
Clinical Sciences Building
Leicester Royal Inﬁrmary
Leicester LE2 7LX
United Kingdom
E-mail: ross.naylor@uhl-tr.nhs.uk
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Always What They Seem
Dr. Naylor, in his commentary on the report by Shishehbor et al.
(1), has brought up an important point regarding the optimal
treatment strategy for patients with asymptomatic unilateral carotid
disease. Since the pivotal trials comparing carotid endarterectomy
with medical therapy almost 2 decades ago (2,3), it has been
accepted that carotid endarterectomy is superior to medical therapy
in lowering the future risk for stroke in patients with asymptomatic
high-grade carotid disease. Whether contemporary medical therapy
with potent antiplatelet, lipid-lowering, and antihypertensive ther-
apy has narrowed the gap between these 2 strategies is unknown.The study by Shishehbor et al. (1) addresses the optimal revas-
cularization strategy before open-heart surgery (OHS), and it was
not designed to address the role of optimal medical therapy before
OHS. The patients included in the study had high-grade carotid
disease and met established indications for carotid revasculariza-
tion. Therefore, the role of medical therapy alone as a long-term
treatment strategy for these patients is irrelevant.
Additionally, Dr. Naylor has quoted us out of context. The
complete statement in our editorial (4) is “This study provides clarity
in the management of patients with carotid and coronary disease
requiring OHS.” The Coronary Artery Bypass Graft Surgery in
Patients With Asymptomatic Carotid Stenosis trial is currently
randomizing patients with asymptomatic severe carotid disease
requiring coronary artery bypass grafting to combined coronary ar-
tery bypass grafting and carotid endarterectomy versus isolated
coronary artery bypass grafting (5). Until the results of this trial are
available, the study by Shishehbor et al. (1) provides a prudent data-
driven strategy for optimal carotid revascularization before OHS.*Ehtisham Mahmud, MD
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Stroke 2012;7:354–60.ReplySometimes, Things Are Not
Always What They SeemWe do share the concerns raised by Dr. Naylor regarding the use of
carotid revascularization for “low-risk” asymptomatic unilateral
carotid disease in the open-heart surgery (OHS) population.
